Canine
Update (June 10, 2026): Oclacitinib Resolves Canine Reactive Histiocytosis in a 10-Dog Case Series
TL;DR
A 2026 retrospective case series of 10 dogs found oclacitinib monotherapy rapidly resolved canine reactive histiocytosis - including cases refractory to other immunomodulators - expanding the recognised off-label uses of this JAK inhibitor beyond atopic dermatitis.
What just dropped
Cain, Lowe and Mauldin published "Treatment of Reactive Histiocytosis With Oclacitinib: A Retrospective Case Series of 10 Dogs" in Veterinary Dermatology (2026; PMID 41603087; DOI 10.1111/vde.70048), from the University of Pennsylvania School of Veterinary Medicine.
- All 10 privately owned dogs were diagnosed with reactive histiocytosis based on clinical history, skin lesions and histopathology, and were treated with oclacitinib as sole therapy.
- All 10 dogs presented with dermal nodules and/or erythematous plaques on the head, trunk or limbs; four also had documented or suspected nasal or oral cavity involvement.
- Seven of the 10 dogs had been treated previously with one or more immunomodulatory agents without durable disease control.
- All dogs were completely responsive to oclacitinib, given at or slightly above the standard antipruritic dosage, with skin and mucosal lesions resolving within 2 to 12 weeks. Four dogs had brief recurrences managed with dosing adjustments.
Context
Oclacitinib (Apoquel) is a selective Janus kinase (JAK) inhibitor licensed for canine allergic and atopic dermatitis. Because JAK signalling is central to many inflammatory and immune-mediated processes, clinicians have explored off-label uses. Reactive histiocytosis is a proliferative disorder of activated interstitial dendritic cells with cutaneous and systemic forms; an immune-mediated cause is suspected, and conventional management has relied on corticosteroids, tetracycline/niacinamide, ciclosporin, azathioprine or leflunomide. This case series reports that oclacitinib produced complete responses even in dogs refractory to those agents, and even where the oral or nasal cavities were involved.
The authors caution that reactive histiocytosis can naturally wax and wane, so a case series cannot prove causation. Still, the rapid, consistent responses across 10 dogs - most of them previously treatment-refractory - make this a clinically meaningful signal worth knowing about.
What this changes in the Oclacitinib (Apoquel) evergreen
The oclacitinib page (https://www.thevoyage.ai/forvets/knowledge/oclacitinib-canine-atopic-dermatitis) centres on JAK inhibition and the atopic dermatitis evidence base. This case series broadens the clinical picture by documenting an emerging off-label use: oclacitinib monotherapy, at or slightly above the standard antipruritic dosage, achieving complete resolution of canine reactive histiocytosis within 2 to 12 weeks in all 10 dogs, including 7 that had failed prior immunomodulatory therapy. This reinforces the drug's broad anti-inflammatory reach beyond pruritus while remaining a small, retrospective, uncontrolled series. Any off-label use should follow current label dosing and individual clinical judgement; this page does not specify dose figures.
References
- Cain CL, Lowe A, Mauldin EA. Treatment of Reactive Histiocytosis With Oclacitinib: A Retrospective Case Series of 10 Dogs. Vet Dermatol. 2026;37(3):419-426. https://pubmed.ncbi.nlm.nih.gov/41603087/
- Mazilu CC, Strichea AH, Solcan G. Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis. Vet Sci. 2026;13(4):403. https://pubmed.ncbi.nlm.nih.gov/42076775/
Voyage Clinical Desk
From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-10-oclacitinib-reactive-histiocytosis
Changelog
- 2026-06-10: First published.
Related reads
References
More clinical updates
Update (June 10, 2026): Bedinvetmab Non-Inferior to Grapiprant for Canine OA Pain on Force-Plate Gait Analysis
A February 2026 randomized non-inferiority trial using force-plate gait analysis found bedinvetmab non-inferior to grapiprant for canine osteoarthritis pain, supporting both as first-line options.
Read →Update (June 10, 2026): No Evidence of Circulating RAAS Activation in Cats with Non-Hypertensive CKD or Untreated Hypertension
A May 2026 JVIM study measuring circulating RAAS peptides in cats found no evidence of classical RAAS activation in non-hypertensive CKD or untreated hypertension, refining the rationale for RAAS-targeted therapy.
Read →Update (June 10, 2026): 2026 Review Maps the Modern Canine Atopic Dermatitis Treatment Toolkit
An April 2026 review maps the current canine atopic dermatitis toolkit - glucocorticoids, cyclosporine, JAK inhibitors, lokivetmab and immunotherapy - reinforcing a multimodal, individualised approach.
Read →Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evidence from pivotal RCTs, a 12-month cohort, and combination therapy data reviewed.
Read →